-+ 0.00%
-+ 0.00%
-+ 0.00%

Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026

Benzinga·10/16/2026 12:38:01
Diffusion vocale

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve throughout a patient's life. The findings will be presented at the Endocrine Nurses Society Annual Symposium 2026, taking place Oct. 16-17 in Phoenix.